Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
1395.6(c) 1407.2(c) 1408.2(c) 1410.8(c) 1420.8(c) Last
3 999 834 5 486 304 5 270 230 4 433 757 4 294 791 Volume
-0.29% +0.83% +0.07% +0.18% +0.71% Change
More quotes
Estimated financial data (e)
Sales 2021 33 519 M 46 092 M 46 092 M
Net income 2021 3 787 M 5 207 M 5 207 M
Net Debt 2021 21 074 M 28 978 M 28 978 M
P/E ratio 2021 18,6x
Yield 2021 5,63%
Sales 2022 35 229 M 48 443 M 48 443 M
Net income 2022 4 589 M 6 311 M 6 311 M
Net Debt 2022 19 680 M 27 062 M 27 062 M
P/E ratio 2022 15,6x
Yield 2022 3,87%
Capitalization 71 110 M 97 886 M 97 784 M
EV / Sales 2021 2,75x
EV / Sales 2022 2,58x
Nbr of Employees 94 066
Free-Float 92,3%
More Financials
Company
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Ratings of GlaxoSmithKline plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GLAXOSMITHKLINE PLC
10/21GLAXOSMITHKLINE : Says CDC Panel Voted to Recommend Approval of Shingles Vaccine Candidate
MT
10/20GLAXOSMITHKLINE : Shingles Vaccine Receives Recommendation in US for Immunocompromised Adu..
MT
10/20Glaxosmithkline plc Announces Unanimous Votes of US Centers for Disease Control and Pre..
CI
10/20GLAXOSMITHKLINE : US Centers for Disease Control and Prevention's Advisory Committee on Im..
PU
10/20GLAXOSMITHKLINE : Viom, GlaxoSmithKline Expand Collaboration Into New Cancer, Autoimmune D..
MT
10/20LESS TALK, MORE ACTION : New report sponsored by ViiV Healthcare provides roadmap to achie..
PU
10/20Viome Life Sciences Announces Expansion of Collaboration with GSK into New Therapeutic ..
CI
10/19'Green is good' says UK's Johnson, wooing Wall Street dollars
RE
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
DJ
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
DJ
10/18GLAXOSMITHKLINE : GSK to showcase significant scientific advances in renal care at the Ame..
PU
10/18Today on Wall Street: This is the real test
10/18GLAXOSMITHKLINE : Berenberg Slashes GlaxoSmithKline's PT, Keeps Rating
MT
10/18GLAXOSMITHKLINE : Berenberg Maintains GlaxoSmithKline At Buy, Trims PT
MT
10/18ANALYST RECOMMENDATIONS : Drax, GlaxoSmithKline, Goldman Sachs, JP Morgan, Steel Dynamics...
More news
News in other languages on GLAXOSMITHKLINE PLC
01:30pL'agenda della prossima settimana -2-
12:38pCOVID : Comm.Ue definisce portafoglio delle 10 cure più promettenti
10:31aBEURSAGENDA : buitenlandse fondsen
01:07aBEURSAGENDA : buitenlandse fondsen
10/21BEURSAGENDA : buitenlandse fondsen
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 14,21 GBX
Average target price 1 602,73 GBX
Spread / Average Target 11 180%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC5.13%97 491
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640